Terminated PHASE2 INTERVENTIONAL 8-arm NCT00215657

Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

An Open-Label, Multi-Center, Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients

Sponsor: Ferring Pharmaceuticals

Conditions Prostate Cancer

Interventions Degarelix

Updated 6 times since 2017 Last updated: May 18, 2011 Started: Mar 31, 2003 Primary completion: Mar 31, 2006 Completion: Mar 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The doses were not effective in maintaining testosterone suppression

Other terminated trials from Ferring Pharmaceuticals

See all terminations from Ferring Pharmaceuticals

Other Prostate Cancer trials with similar outcome

Browse all Prostate Cancer trials

Listed as NCT00215657, this PHASE2 trial focuses on Prostate Cancer and remains terminated or withdrawn. Sponsored by Ferring Pharmaceuticals, it has been updated 6 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Mar 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ferring Pharmaceuticals

Data source: Ferring Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.